Literature DB >> 16777844

RBM4 interacts with an intronic element and stimulates tau exon 10 inclusion.

Amar Kar1, Necat Havlioglu, Woan-Yuh Tarn, Jane Y Wu.   

Abstract

Tau protein, which binds to and stabilizes microtubules, is critical for neuronal survival and function. In the human brain, tau pre-mRNA splicing is regulated to maintain a delicate balance of exon 10-containing and exon 10-skipping isoforms. Splicing mutations affecting tau exon 10 alternative splicing lead to tauopathies, a group of neurodegenerative disorders including dementia. Molecular mechanisms regulating tau alternative splicing remain to be elucidated. In this study, we have developed an expression cloning strategy to identify splicing factors that stimulate tau exon 10 inclusion. Using this expression cloning approach, we have identified a previously unknown tau exon 10 splicing regulator, RBM4 (RNA binding motif protein 4). In cells transfected with a tau minigene, RBM4 overexpression leads to an increased inclusion of exon 10, whereas RBM4 down-regulation decreases exon 10 inclusion. The activity of RBM4 in stimulating tau exon 10 inclusion is abolished by mutations in its RNA-binding domain. A putative intronic splicing enhancer located in intron 10 of the tau gene is required for the splicing stimulatory activity of RBM4. Immunohistological analyses reveal that RBM4 is expressed in the human brain regions affected in tauopathy, including the hippocampus and frontal cortex. Our study demonstrates that RBM4 is involved in tau exon 10 alternative splicing. Our work also suggests that down-regulating tau exon 10 splicing activators, such as RBM4, may be of therapeutic potential in tauopathies involving excessive tau exon 10 inclusion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16777844      PMCID: PMC2072872          DOI: 10.1074/jbc.M603971200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17.

Authors:  L Varani; M Hasegawa; M G Spillantini; M J Smith; J R Murrell; B Ghetti; A Klug; M Goedert; G Varani
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 2.  Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases.

Authors:  M Goedert; R Jakes; R A Crowther; M Hasegawa; M J Smith; M G Spillantini
Journal:  Biochem Soc Trans       Date:  1998-08       Impact factor: 5.407

3.  Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17.

Authors:  M Hong; V Zhukareva; V Vogelsberg-Ragaglia; Z Wszolek; L Reed; B I Miller; D H Geschwind; T D Bird; D McKeel; A Goate; J C Morris; K C Wilhelmsen; G D Schellenberg; J Q Trojanowski; V M Lee
Journal:  Science       Date:  1998-12-04       Impact factor: 47.728

4.  A novel splicing regulator shares a nuclear import pathway with SR proteins.

Authors:  Ming-Chih Lai; Hao-Wei Kuo; Wen-Cheng Chang; Woan-Yuh Tarn
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

5.  5' splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10.

Authors:  A Grover; H Houlden; M Baker; J Adamson; J Lewis; G Prihar; S Pickering-Brown; K Duff; M Hutton
Journal:  J Biol Chem       Date:  1999-05-21       Impact factor: 5.157

6.  Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors.

Authors:  Z H Jiang; W J Zhang; Y Rao; J Y Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17.

Authors:  M Hutton; C L Lendon; P Rizzu; M Baker; S Froelich; H Houlden; S Pickering-Brown; S Chakraverty; A Isaacs; A Grover; J Hackett; J Adamson; S Lincoln; D Dickson; P Davies; R C Petersen; M Stevens; E de Graaff; E Wauters; J van Baren; M Hillebrand; M Joosse; J M Kwon; P Nowotny; L K Che; J Norton; J C Morris; L A Reed; J Trojanowski; H Basun; L Lannfelt; M Neystat; S Fahn; F Dark; T Tannenberg; P R Dodd; N Hayward; J B Kwok; P R Schofield; A Andreadis; J Snowden; D Craufurd; D Neary; F Owen; B A Oostra; J Hardy; A Goate; J van Swieten; D Mann; T Lynch; P Heutink
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

8.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

Authors:  M G Spillantini; J R Murrell; M Goedert; M R Farlow; A Klug; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

9.  Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.

Authors:  M Goedert; M G Spillantini; M C Potier; J Ulrich; R A Crowther
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

10.  Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease.

Authors:  A Ebneth; R Godemann; K Stamer; S Illenberger; B Trinczek; E Mandelkow
Journal:  J Cell Biol       Date:  1998-11-02       Impact factor: 10.539

View more
  29 in total

1.  PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10.

Authors:  Payal Ray; Amar Kar; Kazuo Fushimi; Necat Havlioglu; Xiaoping Chen; Jane Y Wu
Journal:  J Mol Neurosci       Date:  2011-09-01       Impact factor: 3.444

2.  Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.

Authors:  Debra A O'Leary; Orzala Sharif; Paul Anderson; Buu Tu; Genevieve Welch; Yingyao Zhou; Jeremy S Caldwell; Ingo H Engels; Achim Brinker
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

3.  IRAS: High-Throughput Identification of Novel Alternative Splicing Regulators.

Authors:  S Zheng
Journal:  Methods Enzymol       Date:  2016-03-28       Impact factor: 1.600

Review 4.  Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Biochem Pharmacol       Date:  2014-01-10       Impact factor: 5.858

5.  RNA helicase p68 (DDX5) regulates tau exon 10 splicing by modulating a stem-loop structure at the 5' splice site.

Authors:  Amar Kar; Kazuo Fushimi; Xiaohong Zhou; Payal Ray; Chen Shi; Xiaoping Chen; Zhiren Liu; She Chen; Jane Y Wu
Journal:  Mol Cell Biol       Date:  2011-02-22       Impact factor: 4.272

6.  RBM4 modulates the proliferation and expression of inflammatory factors via the alternative splicing of regulatory factors in HeLa cells.

Authors:  Wei-Yang Wang; Weili Quan; Fan Yang; Ya-Xun Wei; Jia-Jun Chen; Han Yu; Jie Xie; Yi Zhang; Zhan-Fei Li
Journal:  Mol Genet Genomics       Date:  2019-09-05       Impact factor: 3.291

7.  LARK activates posttranscriptional expression of an essential mammalian clock protein, PERIOD1.

Authors:  Shihoko Kojima; Ken Matsumoto; Matsumi Hirose; Miyuki Shimada; Mamoru Nagano; Yasufumi Shigeyoshi; Shin-ichi Hoshino; Kumiko Ui-Tei; Kaoru Saigo; Carla B Green; Yoshiyuki Sakaki; Hajime Tei
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-30       Impact factor: 11.205

8.  ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing.

Authors:  Claude C Warzecha; Trey K Sato; Behnam Nabet; John B Hogenesch; Russ P Carstens
Journal:  Mol Cell       Date:  2009-03-13       Impact factor: 17.970

9.  The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression.

Authors:  Yang Wang; Dan Chen; Haili Qian; Yihsuan S Tsai; Shujuan Shao; Quentin Liu; Daniel Dominguez; Zefeng Wang
Journal:  Cancer Cell       Date:  2014-09-08       Impact factor: 31.743

Review 10.  Regulation of alternative splicing of tau exon 10.

Authors:  Wei Qian; Fei Liu
Journal:  Neurosci Bull       Date:  2014-03-14       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.